Published in J Transl Med on May 18, 2011
Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) (2014) 0.89
Amino-functionalized poly(L-lactide) lamellar single crystals as a valuable substrate for delivery of HPV16-E7 tumor antigen in vaccine development. Int J Nanomedicine (2015) 0.75
Fcgamma receptors as regulators of immune responses. Nat Rev Immunol (2008) 11.34
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 6.03
Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem (2005) 4.18
Skin immune sentinels in health and disease. Nat Rev Immunol (2009) 3.52
Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J Virol (1989) 3.01
The human papillomavirus E7 oncoprotein. Virology (2008) 2.32
The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes (2009) 1.63
Papillomavirus E6 and E7 proteins and their cellular targets. Front Biosci (2008) 1.59
Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines (2010) 1.57
Human papillomavirus type 16 E7 protein expressed in Escherichia coli and monkey COS-1 cells: immunofluorescence detection of the nuclear E7 protein. Virology (1989) 1.37
Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding. J Virol (1993) 1.32
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
MHC molecules and microbial antigen processing in phagosomes. Curr Opin Immunol (2009) 1.16
Identification of the nuclear localization and export signals of high risk HPV16 E7 oncoprotein. Virology (2008) 1.11
Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. Int J Cancer (2006) 1.09
Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opin Immunol (2011) 1.08
Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin. Vaccine (2009) 1.05
Genes coding for tumor antigens recognized by human cytolytic T lymphocytes. J Immunother Emphasis Tumor Immunol (1993) 1.05
Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. Hum Gene Ther (2008) 1.00
Structural and functional characterization of the HPV16 E7 protein expressed in bacteria. J Biol Chem (1993) 0.99
Oligomerization properties of the viral oncoproteins adenovirus E1A and human papillomavirus E7 and their complexes with the retinoblastoma protein. Biochemistry (2000) 0.96
Dimerization of the human papillomavirus E7 oncoprotein in vivo. Virology (1995) 0.96
Zinc in innate and adaptive tumor immunity. J Transl Med (2010) 0.95
The HPV16 E7 viral oncoprotein self-assembles into defined spherical oligomers. Biochemistry (2004) 0.94
Identification of domains required for transcriptional activation and protein dimerization in the human papillomavirus type-16 E7 protein. Oncogene (1996) 0.93
Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology (2009) 0.93
Synthesis, phosphorylation, and nuclear localization of human papillomavirus E7 protein in Schizosaccharomyces pombe. Gene (1990) 0.92
High-risk (HPV16) human papillomavirus E7 oncoprotein is highly stable and extended, with conformational transitions that could explain its multiple cellular binding partners. Biochemistry (2002) 0.91
Characterization of functional HPV-16 E7 protein produced in Escherichia coli. J Biol Chem (1992) 0.91
Expression of human papillomavirus proteins in yeast Saccharomyces cerevisiae. Virology (1991) 0.91
Human papillomaviruses as therapeutic targets in human cancer. J Clin Oncol (2011) 0.90
Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection. Cancer Res (2002) 0.90
Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity. Vaccine (2009) 0.89
HPV 16 E7 antibody levels in cervical cancer patients: before and after treatment. J Med Virol (1998) 0.88
Human papillomavirus type 16 E6, E7 and L1 and type 18 E7 proteins produced by recombinant baculoviruses. J Virol Methods (1993) 0.87
Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice. Mol Cancer Ther (2008) 0.87
Cytosolic accumulation of HPV16 E7 oligomers supports different transformation routes for the prototypic viral oncoprotein: the amyloid-cancer connection. Int J Cancer (2009) 0.86
Identification of H-2Kb binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7. Scand J Immunol (1995) 0.85
Immunomodulatory activity of a plant extract containing human papillomavirus 16-E7 protein in human monocyte-derived dendritic cells. Int J Immunopathol Pharmacol (2010) 0.80
Nanovaccines: recent developments in vaccination. J Biosci (2009) 0.80
Expression and purification of His-tagged HPV16 E7 protein active in pRb binding. Protein Expr Purif (2006) 0.80
Chaperone holdase activity of human papillomavirus E7 oncoprotein. Biochemistry (2006) 0.80
Functional oligomerization of purified human papillomavirus types 16 and 6b E7 proteins expressed in Escherichia coli. J Gen Virol (1994) 0.76
Massive secretion by T cells is caused by HIV Nef in infected cells and by Nef transfer to bystander cells. Cell Host Microbe (2009) 1.52
Relationship of up-regulation of 67-kd laminin receptor to grade of cervical intraepithelial neoplasia and to high-risk HPV types and prognosis in cervical cancer. Acta Cytol (2006) 1.42
Assessment of reference values for selected elements in a healthy urban population. Ann Ist Super Sanita (2005) 1.06
Complete genome sequence of a serotype 11A, ST62 Streptococcus pneumoniae invasive isolate. BMC Microbiol (2011) 1.03
Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Virology (2004) 0.99
Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins. Infect Agent Cancer (2006) 0.99
Characterization of adherent-invasive Escherichia coli isolated from pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis (2011) 0.99
Point mutations in wchA are responsible for the non-typability of two invasive Streptococcus pneumoniae isolates. Microbiology (2011) 0.96
Effect of acid adaptation on the fate of Listeria monocytogenes in THP-1 human macrophages activated by gamma interferon. Infect Immun (2002) 0.93
Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology (2009) 0.93
Survivin as a marker of cervical intraepithelial neoplasia and high-risk human papillomavirus and a predictor of virus clearance and prognosis in cervical cancer. Am J Clin Pathol (2005) 0.90
Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein. Int J Cancer (2012) 0.90
Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer. Am J Clin Pathol (2004) 0.90
Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection. Cancer Res (2002) 0.90
Bovine lactoferrin prevents the entry and intercellular spread of herpes simplex virus type 1 in Green Monkey Kidney cells. Antiviral Res (2007) 0.89
Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer (2008) 0.89
Characterization of antibodies in single-chain format against the E7 oncoprotein of the human papillomavirus type 16 and their improvement by mutagenesis. BMC Cancer (2007) 0.87
Isolation and partial characterization of bacteriophages infecting Pseudomonas syringae pv. actinidiae, causal agent of kiwifruit bacterial canker. J Basic Microbiol (2014) 0.86
Antiviral activity of lactoferrin towards naked viruses. Biometals (2004) 0.86
Identification of novel linear megaplasmids carrying a ß-lactamase gene in neurotoxigenic Clostridium butyricum type E strains. PLoS One (2011) 0.85
Distinct properties of the egress-related osmiophilic bodies in male and female gametocytes of the rodent malaria parasite Plasmodium berghei. Cell Microbiol (2014) 0.85
Intracellular anti-E7 human antibodies in single-chain format inhibit proliferation of HPV16-positive cervical carcinoma cells. Int J Cancer (2005) 0.84
In vivo antitumor effect of an intracellular single-chain antibody fragment against the E7 oncoprotein of human papillomavirus 16. Int J Cancer (2013) 0.84
Heparin-interacting sites of bovine lactoferrin are involved in anti-adenovirus activity. J Med Virol (2003) 0.83
Seroprevalence of Toscana virus in blood donors, France, 2007. Emerg Infect Dis (2011) 0.83
Recombinant protein-based ELISA and immuno-cytochemical assay for the diagnosis of SARS. J Med Virol (2005) 0.83
Over-expression of topoisomerase IIalpha is related to the grade of cervical intraepithelial neoplasia (CIN) and high-risk human papillomavirus (HPV), but does not predict prognosis in cervical cancer or HPV clearance after cone treatment. Int J Gynecol Pathol (2006) 0.82
Effect of bovine lactoferricin on enteropathogenic Yersinia adhesion and invasion in HEp-2 cells. J Med Microbiol (2004) 0.82
Bovine lactoferrin inhibits adenovirus infection by interacting with viral structural polypeptides. Antimicrob Agents Chemother (2003) 0.82
Retinoblastoma-independent antiproliferative activity of novel intracellular antibodies against the E7 oncoprotein in HPV 16-positive cells. BMC Cancer (2011) 0.81
Bovine lactoferrin inhibits influenza A virus induced programmed cell death in vitro. Biometals (2010) 0.81
Generation and characterization of a stable cell population releasing fluorescent HIV-1-based Virus Like Particles in an inducible way. BMC Biotechnol (2006) 0.81
Biomonitoring of tram drivers exposed to airborne platinum, rhodium and palladium. Int Arch Occup Environ Health (2007) 0.81
Bovine lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza virus. Pathog Glob Health (2012) 0.81
Lactoferricin influences early events of Listeria monocytogenes infection in THP-1 human macrophages. J Med Microbiol (2004) 0.80
Lactoferrin inhibits early steps of human BK polyomavirus infection. Antiviral Res (2006) 0.80
Bovine lactoferrin peptidic fragments involved in inhibition of Echovirus 6 in vitro infection. Antiviral Res (2005) 0.80
Human antibody response to Toscana virus glycoproteins expressed by recombinant baculovirus. J Med Virol (2002) 0.80
Immunization with Toscana virus N-Gc proteins protects mice against virus challenge. Virology (2008) 0.79
Bovine lactoferrin inhibits echovirus endocytic pathway by interacting with viral structural polypeptides. Antiviral Res (2006) 0.78
Antiadenovirus activity of milk proteins: lactoferrin prevents viral infection. Antiviral Res (2002) 0.78
Bovine lactoferrin: involvement of metal saturation and carbohydrates in the inhibition of influenza virus infection. Biochem Cell Biol (2012) 0.78
Distribution and elimination of palladium in rats after 90-day oral administration. Toxicol Ind Health (2010) 0.77
Environmental and biological monitoring of iridium in the city of Rome. Chemosphere (2007) 0.77
Mucosal and cutaneous human papillomaviruses detected in raw sewages. PLoS One (2013) 0.76
Exposure of rome city tram drivers to airborne platinum, rhodium, and palladium. J Occup Environ Med (2008) 0.76
Generation of human antibody fragments recognizing distinct epitopes of the nucleocapsid (N) SARS-CoV protein using a phage display approach. BMC Infect Dis (2005) 0.76
Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling. Int J Gynecol Pathol (2008) 0.76
Monitoring Pt and Rh in urban aerosols from Buenos Aires, Argentina. Sci Total Environ (2005) 0.75
Clinical and epidemiological correlates of antibody response to human papillomaviruses (HPVs) as measured by a novel ELISA based on denatured recombinant HPV16 late (L) and early (E) antigens. Infect Agent Cancer (2008) 0.75
Bovine lactoferrin interacts with cable pili of Burkholderia cenocepacia. Biometals (2010) 0.75
Infection of a simian B cell line by human and simian immunodeficiency viruses. AIDS Res Hum Retroviruses (2004) 0.75
Inhibitory activity of bovine lactoferrin against echovirus induced programmed cell death in vitro. Int J Antimicrob Agents (2005) 0.75
Platinum, palladium and rhodium content in road dust, tunnel dust and common grass in Białystok area (Poland): a pilot study. Sci Total Environ (2004) 0.75
Cancer 'chemotherapia specifica' ninety years after Paul Ehrlich. Chemotherapy (2007) 0.75
Invasion of HeLa cells by Enterococcus faecalis clinical isolates. Med Microbiol Immunol (2002) 0.75